Benitec said this week that it has received a $161,674 dividend related to its stake in privately held RNAi drug shop Tacere Therapeutics.
In 2006, Benitec licensed its gene-silencing technology to Tacere for use in developing an expressed RNA-based treatment for hepatitis C (GSN 10/12/2006). The equity stake was part of the payment Benitec received for the license.